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In a double blind study, the immunomodulator dmg levamisole was administered along with 
chloropromazine to 18 schizophrenic patients, and efficiency of the combination was compared to that 
of chloropromazine along with placebo administered to 16 schizophrenic patients. Hie decrease in T 
suppressor cell count found in both groups at benchmark was found to be corrected in the patients 
receiving levamisole and this increase in T suppressor cell count was significantly correlated with the 
iinprovemnt in psychosis. Tlie findings provide evidence in favour of the autoimmune hypothesis of 
schizophrenia. 
Though a considerable amount of re-
search has been done in relation to the autoim-
mune hypothesis, it continues to be 
controversial (Ganguli et al., 1987; Koljaskine 
and Prilipko, 1988). Vartanian and Koljaskine 
(1987) found a hyperactive B-cell response 
(resulting in increased immunoglobulins) in 
schizophrenic patients, associated with altered 
T suppressor cell functioning. Based on this 
observation, these authors studied the 
therapeutic effect of correcting T suppressor 
cell functioning using an immunomodulator, 
levamisole, and reported encouraging positive 
results in some schizophrenics. The present 
study was carried out to study the therapeutic 
efficacy of levamisole as an adjunct to 
chlorpromazine employing a more rigours 
study design. 
MATERIAL AND METHODS 
34 male schizophrenics fulfilling Re-
search Diagnostic Criteria for Schizophrenia 
(Spitzer et al. 1978), and a set of predefined 
inclusion and exclusion criteria were selected 
for the study. Patients were thoroughly inves-
tigated to exclude any physical disease. The 
baseline (day 0) psychiatric assessment was 
done on Modofied Brief Psychiatric Rating 
Scale (MBPRS; Overall and Gorham, 1962) 
and on the sign and symptoms scale for 
Neuroleptics (WHO, 1986) within three days of 
hospitalization, and subsequently on days 21 
and 42 of the study. Patients were randomly 
assigned to either chlorpromazine with 
levamisole group (Group 1; N = 18) or to 
chlorpromazine and placebo group (Group 2; 
N = 16). Levamisole or placebo, respectively, 
were administered on a double-blind basis. 
Chlorpromazine was administered in doses of 
15 mg/kg body weight per day through the study 
period (6 weeks) and levamisole in doses 150mg 
at bedtime twice a week. Estimations of T and 
B lymphocytes were done employing the tech-
nique developed by Kapoor et a/.(1980) which 
is a modification of Coulson and Chalmers' 
(1964) technique, on day 0, 21 & 42. The T 
suppressor lymphocytes on these days were es-
timated by the technique of Gupta et a/.(1983). 
The data was statistically analysed employing 
the student's 't' test and Pearsons' correlation 
coefficient. 
OBSERVATIONS AND RESULTS 
Both groups of patients were com-
parable for age and body weight. There was no 
significant difference between the two groups 
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Table 1 - Illness Characteristics Of Sample 
Illness variables 
Age of onset 
upto 20 years 
> 20 Years 
Duration 
upto 2 years 
2 years 
No. of episodes 
upto 2 episodes 
2 episodes 
Experimental Group (N = 
5 
13 
X
2 = 0.049, d.f. = l,N.S 
9 
9 
X
2=0.54,d.f. = l,N.S. 
11 
7 
X
2 = 0.08,d.f. = l,N.S. 
18)  Control Group (N = 16) 
5 
11 
6 
10 
9 
7 
Table 2- MBPRS scores and lymphocyte counts in Exp. and Control groups 
Experimental group (N = 18) 
Day 0 (a)  Day 21(b)  Day 42 (c) 
Control group (N = 16) 
Day 0(d)  Day 21(e) Day 42(0 
MBPRS Scores  31.0  15.5  2.4  30.1  16.2 
a vs. b: p<0.01; a vs. c: p< 0.001; d vs. e: p < 0.001; d vs. f: p< 0.001 
a vs. d: N.S.; b vs. e: N.S.; c vs. f: p < 0.05 
T lymphocytes Count 
(in %)  31.2 30.9 31.1 30.2 
All comparisons are not significant 
30.2  30.4 
T lymphocytes Count 
(in %)  58.2 58.5 58.7 58.2 
All significants are not significant 
58.4  58.7 
T suppressor lymphocyte 17.8  19.0  21.1  16.9  17.1  17.2 
a vs. b: p < 0.01; a vs. c: p < 0.001; d vs. e: N.S.; d vs. f: N.S. 
a vs. d: N.S.; b vs. e: p < 0.01; c vs. f: p < 0.01 IMMUNOMODULATOR IN THETREATMENT OF SCHIZOPHRENIA 275 
Table 3- Coefficient of correlation between the changes in MBPRS scores and lymphocytes in 
the two groups 
Correlation between changes 
from baseline in 
MBPRS scores with 
B Cells 
T Cells 
T suppressor cells 
On day 21 
Experimental 
group 
+ 0.06 
-0.37 
-0.11 
Control 
group 
-0.09 
-0.06 
-0.33 
On day 42 
Experimental 
group 
-0.26 
-0.04 
-oho** 
Control 
group 
-0.13 
-0.06 
-0.48 
**p<0.01 
Table 4- T-Suppressor lymphocyte counts in experimental and control groups 
Experimental group (N = 18) 
Non-chronic (N=9) | Chronic (N = 9) 
Day 0(a) Day 21(b) Day 42(c) Day 0(d) Day 21(e) 
19.9 19.8 20.0 15.6 18.7 
a vs. d: p< 0.001; (a-b) vs. (d-e): p< 0.001; (a-c) vs. (d-f): p< 0.001 
Control group (N = 16) 
Non-chronic (N = 9) .  Chronic (N=9) 
Day 0(a) Day 21(b) Day 42(c) Day 0(d) Day 21(e) 
19.8 20.0 20.0 15.2 15.3 
a vs. d: p; < 0.05 (a-b) vs. (d-e): N.S.; (a-c) vs. (d-f): N.S. 
Day 42 (f) 
20.1 
Day 42 (f) 
15.5 276  S.AGARWAL«fo/. 
on variables such as age of onset, total duration 
of illness, and number of episodes(Table-1). 
The corrected mean MBPRS scores and 
lymphocytes counts on baseline, on day 21 and 
on day 42 in the experimental and control 
groups are shown in Table 2. Patients in both 
the groups showed significant improvement 
(p < 0.001) on day 21 and at the end of the study 
when compared to the base line. Patients reciv-
ing levamisole (Group 1) had significantly lower 
scores on MBPRS than the placebo (Group 2) 
at the end of the study (p < 0.05). 
B & T lymphocytes counts remained al-
most similar throughout the study in both the 
groups, whereas T suppressor lymphocyte 
count showed significant increase on day 21 and 
on day 42 from baseline (P < 0.01 & p < 0.001, 
respectively) in the experimental group, but 
not in the control group, it was found that the 
increment in T suppressor cells was statistically 
significant in the experimental group on days 21 
and 42 (P <0.01). The coeficient of correlation 
between the changes in MBPRS and the lym-
phocytes revealed that the increments in T sup-
pressor cells were significantly correlated with 
the reductions in MBPRS scores in the ex-
perimental group (P<0.01) at the end of the 
study (Table 3)- There was no change in T & 
B lymphocytes. 
When nonchronic and chronic sub-
groups were compared, levamisole was not 
found to exert any beneficial effect either on 
mean MBPRS scores or on lymphocyte counts 
in the nonchronic subgroups of experimental 
patients, both on Student's T test and coeffi-
cient of correlation. However, in the chronic 
subgroup of schizophrenics, levamisole was 
found to be an effective adjunct both in terms 
of incresing T suppressor lymphocytes counts 
and in reducing the mean MBPRS scores at 
statistically significant levels, on both Student's 
V test (P < 0.001) and on ceofficient of correla-
tion (P< 0.005). 
When MBPRS score and lymphocyte 
counts of the chronic and nonchronic sub-
groups of schizophrenics were compared in the 
experimental and control groups it emerged 
that the difference in the MBPRS scores as well 
as T & B lymphocytes counts at baseline were 
nonsignificant in the experimental and control 
groups, but the T suppresor lymphocyte count 
was significantlu lower in the chronic subgroup 
in comparison to nonchronic subgroup of the 
experimental (P< 0.001) and control groups 
(P<0.05) (Table 4 ). Further, in the ex-
perimental group, the T suppresor lymphocytes 
increased gradually with treatment in the 
chronic subgroup and became almost equal to 
those of the non- chronic subgroup, while in the 
control group there was no change in the T 
suppressor cell lymphocyte count. All the side-
effects noted were those of chlorpromazine and 
none were attributable to levamisole. 
DISCUSSION 
This is the first attempt inour country to 
study the role of an immunomodulator, 
levamisole, as an adjunct in the treatment of 
schizophrenia. The results of the study indicate 
the beneficial effects of levamisole as an adjunct 
to chlorpromazine, atleast in schizophrenics 
having total duration of illness more than two 
years (chronic). The beneficial effects of 
levamisole were manifest in marked reduction 
of MBPRS mean scores and increments in T-
suppressor lymphocytes. Previous studies of 
this therapeutic modality, limited to the USSR, 
showed similar results (Vertanian and Koljas-
kina, 1987; Mikheva et at., 1987). However, ti»? 
sample size, was small in both the studies. 
The results of the study also provide in-
direct evidence in favour of the autoimmune 
hypothesis of schizophrenia. Immunological 
parameters of diagnostic importance in autoim-
mune diseases include autoantibodies, immune 
complexes, and immunoglobuline in the serum IMMUNOMODULATOR IN THE TREATMENT OF SCHIZOPHRENIA 27 7 
which are elevated and serum complements and 
T suppressor cells is an important diagnostic 
indicator which was found to be decreased in 
the present study. However, the other 
parameters such as immunoglobulinc (IgG, IgA 
& IgM), and complement (C3 & C4) which were 
also investigated, did not show any difference 
(Agarwal, 1990) Thus, not all the findings ex-
pected on the basis of the autoimmune 
hypothesis of schizophrenia have been found, 
and further research with a larger sample, 
homogenous for chronicity, is indicated. 
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